Related Experiment Videos
Nitrovasodilator-induced inhibition of LTB4 release from human PMN may be mediated by cyclic GMP
1Institut für Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Federal Republic of Germany.
Abstract:
This study investigates the action of nitrovasodilators on f-metleu-phe (FMLP)-stimulated LTB4 release and intracellular cyclic nucleotide levels in human polymorphonuclear leukocytes (PMN). Sodium nitroprusside, and the molsidomine (MOL) metabolites SIN-1 and SIN-1A potently inhibited LTB4 release and increased cGMP levels. No significant effects on LTB4 release or cGMP accumulation were observed in the presence of molsidomine or glyceryl trinitrate. None of the compounds tested affected cAMP levels. It is suggested that nitrovasodilators (i) inhibit LTB4 release from human PMN via enhanced cGMP and (ii) that this inhibition requires the presence of an active metabolite, probably nitric oxide.
Insights
Nitrovasodilators, like sodium nitroprusside, inhibit leukotriene B4 (LTB4) release from human polymorphonuclear leukocytes (PMN) by increasing cyclic guanosine monophosphate (cGMP). This effect requires an active metabolite, likely nitric oxide.
Area of Science:
- Immunopharmacology
- Cellular signaling
Background:
- Leukotriene B4 (LTB4) is a key mediator in inflammatory responses.
- Polymorphonuclear leukocytes (PMN) are crucial immune cells involved in inflammation.
- Nitrovasodilators are known for their vasodilatory effects, but their impact on immune cell function is less understood.
Purpose of the Study:
- To investigate the effects of nitrovasodilators on LTB4 release from human PMN.
- To examine the influence of nitrovasodilators on intracellular cyclic nucleotide levels (cGMP and cAMP) in PMN.
- To elucidate the mechanism by which nitrovasodilators modulate PMN inflammatory mediator release.
Main Methods:
- Human PMN were stimulated with f-metleu-phe (FMLP).
- LTB4 release was measured using specific assays.
- Intracellular levels of cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) were quantified.
- Various nitrovasodilators and their metabolites were tested, including sodium nitroprusside, molsidomine (MOL), SIN-1, SIN-1A, and glyceryl trinitrate.
Main Results:
- Sodium nitroprusside, SIN-1, and SIN-1A significantly inhibited FMLP-stimulated LTB4 release.
- These active nitrovasodilator metabolites also potently increased intracellular cGMP levels in PMN.
- Molsidomine and glyceryl trinitrate did not show significant effects on LTB4 release or cGMP levels.
- None of the tested compounds affected intracellular cAMP levels.
Conclusions:
- Nitrovasodilators inhibit LTB4 release from human PMN, likely mediated by enhanced intracellular cGMP.
- The inhibitory action of nitrovasodilators on PMN requires the presence of an active metabolite, presumed to be nitric oxide.
- These findings suggest a potential immunomodulatory role for specific nitrovasodilators in inflammatory conditions involving PMN.